State Street Corp Lowers Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

State Street Corp decreased its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 6.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,485,156 shares of the biopharmaceutical company's stock after selling 173,932 shares during the quarter. State Street Corp owned 3.75% of Celldex Therapeutics worth $84,470,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of CLDX. KBC Group NV raised its position in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 495 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Celldex Therapeutics in the 2nd quarter valued at approximately $76,000. Los Angeles Capital Management LLC raised its position in shares of Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company's stock valued at $273,000 after buying an additional 638 shares in the last quarter. Quest Partners LLC raised its position in shares of Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company's stock valued at $273,000 after buying an additional 6,879 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock valued at $291,000 after buying an additional 1,504 shares in the last quarter.

Celldex Therapeutics Stock Down 0.5 %

CLDX traded down $0.14 during trading on Tuesday, hitting $26.06. 295,321 shares of the company's stock were exchanged, compared to its average volume of 885,752. The business's 50 day moving average is $27.19 and its two-hundred day moving average is $33.58. Celldex Therapeutics, Inc. has a fifty-two week low of $22.93 and a fifty-two week high of $53.18. The stock has a market cap of $1.73 billion, a P/E ratio of -10.19 and a beta of 1.57.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company raised shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Wednesday, November 20th. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They set a "neutral" rating and a $45.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 16th. Finally, Citigroup assumed coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a "buy" rating and a $70.00 price target on the stock. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $62.25.

Insider Transactions at Celldex Therapeutics

In other Celldex Therapeutics news, CEO Anthony S. Marucci bought 11,500 shares of the business's stock in a transaction on Monday, November 11th. The stock was purchased at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.80% of the company's stock.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.